EP0708764A1 - Enanthioselective preparation of thiazole derivatives - Google Patents

Enanthioselective preparation of thiazole derivatives

Info

Publication number
EP0708764A1
EP0708764A1 EP94910017A EP94910017A EP0708764A1 EP 0708764 A1 EP0708764 A1 EP 0708764A1 EP 94910017 A EP94910017 A EP 94910017A EP 94910017 A EP94910017 A EP 94910017A EP 0708764 A1 EP0708764 A1 EP 0708764A1
Authority
EP
European Patent Office
Prior art keywords
borane
process according
reaction inert
formula
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94910017A
Other languages
German (de)
French (fr)
Inventor
George Joseph Quallich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of EP0708764A1 publication Critical patent/EP0708764A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds

Definitions

  • This invention relates to a particularly useful process for preparing the compounds of formulas (I) and (II),
  • optically pure compounds of formulas (I) and (II) are useful intermediates in the synthesis of useful antidiabetic compounds of formula (IV),
  • the present invention provides a process for enantioselectively preparing the compound of formula (I)
  • R 1 is hydrogen, (C,-C 8 )alkyl, benzyl, heterocyclyl or phenyl optionally substituted independently with up to three (C,-C 8 )alkyl, (C C 8 )alkoxy or halo groups;
  • R 2 and R 3 are syt7, are taken separately, and are each independently (O,-C 8 )alkyl, benzyl, heterocyclyl or phenyl optionally substituted with up to three (C ⁇ CoJalkyl, (C,- C 8 )alkoxy or halo groups, provided that when R 2 is CH 3 and R 3 is phenyl, R 1 is H, or with a chiral oxazaborolidine catalyst of the formula (VI),
  • R 1 is as defined above and D is a cis-fused 4-6 membered carbomonocyclic ring optionally substituted independently with up to three (C,-C 8 )alkyl, heterocyclyl or phenyl optionally substituted independently with up to three (C
  • a preferred process of this invention is the above process wherein said oxazaborolidine catalyst is
  • a particularly preferred process within the preferred process is the process wherein said reaction inert solvent is tetrahydrofuran, dioxane, diethyl ether, toluene or benzene; said reaction inert atmosphere is nitrogen and said borane reducing agent is borane methylsulfide complex.
  • a more particularly preferred process within the particularly preferred process is the process wherein said chiral oxazaborolidine catalyst is prepared in situ prior to the addition of said prochiral ketone of formula (III).
  • the present invention also provides a process for enantioselectively preparing the compound of the formula (II),
  • the present invention provides a process for preparing the optically active compounds of formulas (I) and (II) hereinabove in substantially enantiomerically pure form.
  • the scheme for this process is shown in Scheme I, below.
  • the process of this invention is readily carried out.
  • the compound of formula (I) is prepared in substantially enantiomerically pure form via the reduction of the prochiral ketone, 4-bromoacetyl-2-trifluoromethylthiazole (III).
  • the precursor to the chiral oxazaborolidine catalyst in the form of a chiral 1 ,2-disubstituted aminoethanol derivative, is dissolved in a reaction inert solvent under a reaction inert atmosphere at ambient temperature.
  • the chiral 1 ,2-disubstituted amino-ethanol derivative can be chosen from among any of the 1 ,2-disubstituted aminoethanol derivatives which give rise to the chiral oxazaborolidine catalysts which are used in the process of this invention.
  • preferred 1 ,2-disubstituted amino-ethanol derivatives are (1S, 2R)- (+)-2-amino-1 ,2-diphenylethanol and (1S, 2R)-(+)-norephedrine.
  • the reaction inert solvents which are particularly preferred include but are not limited to dioxane, tetrahydrofuran, diethyl ether, toluene and benzene. More particularly preferred solvents are tetrahydrofuran and toluene.
  • a suitable borane reducing agent is added to the reaction mixture and the reaction mixture is left at ambient temperature for 2 to 24 hours.
  • the borane reducing agent may be selected from borane methylsulfide complex and borane tetrahydrofuran complex, but most preferred is borane methylsulfide complex.
  • the chiral oxazaborolidine catalyst will have formed within 10-16 hours.
  • the prochiral ketone of formula (III) is added to the reaction mixture at ambient temperature.
  • the reaction reducing the ketone to the alcohol is generally complete within 10-15 minutes after addition is complete. However, occasionally a longer amount of time may be required to ensure complete reaction depending upon a variety of factors including the particular solvents chosen or amounts of materials used and so on.
  • the reaction mixture is then cooled, generally to about 0°C, and quenched by the careful addition of a proton source, generally methanol.
  • the compound of formula (I) is isolated according to the standard methods of organic chemistry.
  • the reduction process of this invention can be carried out by reacting a prochiral ketone of the formula R 4 R 5 CO, wherein R 4 and R 5 are defined hereinbelow with a borane reducing agent in the presence of a chiral oxazaborolidine catalyst according to formula (V) or formula (VI).
  • Said process results in the enantioselective reduction of said prochiral ketone, such that only one of two possible alcohol enantiomers is formed in preference to the corresponding enantiomer.
  • the degree of enantio-selectivity which is obtained will vary depending upon the size of the R 4 and R 5 groups attached to the carbonyl group forming the prochiral ketone.
  • the degree of enantioselection will be lower. As the R 4 and R s groups become increasingly disparate in size, the degree of enantio ⁇ selection will be greater. However, it should be understood that the size of the R 4 and R 5 groups is not the sole determining factor affecting the degree of enantioselectivity achieved. Ordinarily, with prochiral ketones wherein R 4 and R 5 are at least moderately different in size, at least 90% of the desired enantiomer will be obtained. However, typically greater than 90% of the desired enantiomer is obtained
  • the prochiral ketone is dissolved in a suitable reaction inert solvent such as toluene, diethyl ether, dioxane, tetrahydrofuran or the like. Preferred is tetrahydrofuran.
  • a catalytically effective amount of a chiral oxazaborolidine compound of formula (V) or formula (VI) is added to the reaction mixture at from about -78°C to about room temperature, preferably at room temperature; however, the preferred temperature will vary depending upon the particular borane reducing agent being used.
  • the preferred amount of said catalyst is about 5-10 mole % with, respect to said ketone.
  • reaction mixture is then treated slowly with about 4.2 hydride equivalents of a borane reducing agent such as borane dimethylsulfide complex, borane tetrahydrofuran complex, catecholborane or the like.
  • a borane reducing agent such as borane dimethylsulfide complex, borane tetrahydrofuran complex, catecholborane or the like.
  • additional hydride equivalents of reducing agent are necessary.
  • borane dimethylsulfide complex is preferred for its ease of use.
  • the reducing agent is added at a rate which modulates the rate of the catalytic reduction. The reaction is sometimes complete as soon as all of the reducing agent has been added, as can be determined by monitoring the course of the reaction via thin layer chromatography according to the standard practice of organic chemistry.
  • reaction mixture may be stirred at about room temperature for about fifteen minutes.
  • the temperature of reaction mixture is then adjusted to 0°C and quenched with a proton source.
  • Said proton source usually a lower alkanol such as methanol, is added slowly to control the exothermic reaction.
  • the product is isolated by removing the solvent in vacuo followed by partitioning between an organic solvent and an aqueous acid followed by separation of layers and purification according to the standard techniques of organic chemistry.
  • the compound of formula (II) of this process is also readily prepared.
  • the compound of formula (I) is dissolved in aqueous base and vigorously stirred.
  • the preferred base is sodium hydroxide, however other bases such as potassium hydroxide and potassium t-butoxide may also be utilized.
  • the debromination and cyclization of the compound of formula (I) to the epoxide of formula (II) is effected rapidly and without racemization of the chiral center. Generally the reaction is complete within 5 to 10 minutes, however the reaction may require longer periods depending upon a variety of factors including strength of base, nature of base, amount of materials used and so on.
  • the epoxide is isolated from the reaction mixture utilizing well-known methods of organic chemistry.
  • the chiral 1 ,2-disubstituted aminoethanol derivatives are generally readily available from commercial sources such as Aldrich or Sigma. Where the chiral 1 ,2- disubstituted aminoethanol derivative is not readily available, said erythro aminoethanol derivatives are prepared by methods well known to those of ordinary skill in the art, such as provided by Reetz et al., Angew. Chemie Int. Ed. Eng., 26, 1987, 1141-43 and Matsunaga et al., Tetrahedron Letters, 32, 1991. 7715-18.
  • Alkyl means a branched or unbranched saturated hydrocarbon group containing the specified number of carbon atoms, e.g., C-,-C 8 . Examples include, but are not limited to methyl, ethyl, isopropyl, n-butyl, t-butyl and the like.
  • Alkoxy means a branched or unbranched saturated hydrocarbon containing the specified number of carbon atoms and a single oxygen atom by which said hydrocarbon is attached to a central backbone. Examples include, but are not limited to methoxy, ethoxy and the like.
  • Heterocyclyl means a 5- or 6-membered aromatic group containing up to three heteroatoms, each of said heteroatoms selected from N, O and S and which may be optionally benzo-fused, said heterocyclyl group being optionally substituted independently with up to three (C-,-C 8 )alkyl, (C-,-C 8 )alkoxy or halo groups.
  • a “prochiral ketone”, denoted by R 4 R CO, is a ketone in which R 4 and R 5 are non-identical, so that the secondary alcohol reduction product R 4 R s CHOH has a chiral center at the alcohol carbon.
  • R 4 and R 5 are taken together, forming a ring including the ketone, and that the ring so formed has no plane of symmetry across a plane drawn perpendicular to the plane containing the carbonyl group and the two carbon atoms attached directly thereto, said plane containing both the carbon and oxygen atoms of the carbonyl group as points therein.
  • Reaction inert solvent means a solvent which does not interact with the reactants, intermediates or products in such a way that adversely affects the yield of the desired products.
  • "Syn" means that the substituents substituted on adjacent ring carbon atoms are located on the same side of a plane which encompasses the bond between said carbon atoms and the bonds by which each of said carbon atoms are attached to the ring.
  • Enantiomeric excess or e.e., is the excess of one of two enantiomers over the other, usually expressed as a percentage, i.e., a 90% e.e. reflects the presence of 95% of one enantiomer and 5% of the other in the material in question.
  • "Ambient temperature” means the temperature of the immediate external environment surrounding the reaction flask. This temperature is usually room temperature (20°-25°C).
  • reaction inert atmosphere means a gas which does not interact with the reactants, intermediates or products in such a way that adversely affects the yield of the desired products.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

An enanthioselective process for preparing the compounds of formulas (I) and (II) from the prochiral ketone precursor of the alcohol of formula (I). The compounds of formulas (I) and (II) are thus obtained in substantially enantiomerically pure form by reducing the ketone with a borane reducing agent in the presence of a chiral oxazaborolidine catalyst.

Description

ENANTHIOSELECTIVE PREPARATION OF THIAZOLE DERIVATIVES Background of the Invention This invention relates to a particularly useful process for preparing the compounds of formulas (I) and (II),
( i ) π ι >
in substantially enantiomerically pure form by enantioselectively reducing the prochiral ketone of formula (III)
( I I I )
with a borane reducing agent in the presence of an oxazaborolidine catalyst. The optically pure compounds of formulas (I) and (II) are useful intermediates in the synthesis of useful antidiabetic compounds of formula (IV),
(IV)
which are disclosed in U.S.4,886,814, and which is incorporated herein by reference.
Summary of the Invention The present invention provides a process for enantioselectively preparing the compound of formula (I)
(I) in substantially enantioselectively pure form. The process of this invention comprises reacting the prochiral ketone of formula (III),
(III) with a borane reducing agent in the presence of a chiral oxazaborolidine catalyst of the formula (V),
R1
( V ) wherein R1 is hydrogen, (C,-C8)alkyl, benzyl, heterocyclyl or phenyl optionally substituted independently with up to three (C,-C8)alkyl, (C C8)alkoxy or halo groups; R2 and R3 are syt7, are taken separately, and are each independently (O,-C8)alkyl, benzyl, heterocyclyl or phenyl optionally substituted with up to three (C^CoJalkyl, (C,- C8)alkoxy or halo groups, provided that when R2 is CH3 and R3 is phenyl, R1 is H, or with a chiral oxazaborolidine catalyst of the formula (VI),
( V I )
wherein R1 is as defined above and D is a cis-fused 4-6 membered carbomonocyclic ring optionally substituted independently with up to three (C,-C8)alkyl, heterocyclyl or phenyl optionally substituted independently with up to three (C|-C8)alkyl, (O,-C8)alkoxy or halo groups; a cis-fused 6-9 membered carbobicyclic system optionally substituted independently with up to three (C.,-C8)alkyl, heterocyclyl or phenyl optionally substituted independently with up to three (C-,-C8)alkyl, (C.,-CB)alkoxy or halo groups; or a cis-fused system having the structure R6 and R7 are each independently
H, (C-,-C8)alkyl, (C,-C8)alkoxy or halo, in a reaction inert solvent under a reaction inert atmosphere.
A preferred process of this invention is the above process wherein said oxazaborolidine catalyst is
H H
( V I I ) ( V I I I )
A particularly preferred process within the preferred process is the process wherein said reaction inert solvent is tetrahydrofuran, dioxane, diethyl ether, toluene or benzene; said reaction inert atmosphere is nitrogen and said borane reducing agent is borane methylsulfide complex.
A more particularly preferred process within the particularly preferred process is the process wherein said chiral oxazaborolidine catalyst is prepared in situ prior to the addition of said prochiral ketone of formula (III). The present invention also provides a process for enantioselectively preparing the compound of the formula (II),
( I I )
which comprises preparing the compound of formula (I) as described hereinabove and reacting said compound of formula (I) with a base to form the compound of formula (II) in substantially enantiomerically pure form.
Detailed Description of the Invention The present invention provides a process for preparing the optically active compounds of formulas (I) and (II) hereinabove in substantially enantiomerically pure form. The scheme for this process is shown in Scheme I, below.
chiral 1 ,2-d i substi tuted borane reduc ing (III) aminoe thanol + a9en t
Borane reducing agent chiral catalyst
( I I I ) ( I )
( I I )
SCHEME I
The process of this invention is readily carried out. The compound of formula (I) is prepared in substantially enantiomerically pure form via the reduction of the prochiral ketone, 4-bromoacetyl-2-trifluoromethylthiazole (III).
In the reduction process of this invention, the precursor to the chiral oxazaborolidine catalyst, in the form of a chiral 1 ,2-disubstituted aminoethanol derivative, is dissolved in a reaction inert solvent under a reaction inert atmosphere at ambient temperature. The chiral 1 ,2-disubstituted amino-ethanol derivative can be chosen from among any of the 1 ,2-disubstituted aminoethanol derivatives which give rise to the chiral oxazaborolidine catalysts which are used in the process of this invention. However, preferred 1 ,2-disubstituted amino-ethanol derivatives are (1S, 2R)- (+)-2-amino-1 ,2-diphenylethanol and (1S, 2R)-(+)-norephedrine. The reaction inert solvents which are particularly preferred include but are not limited to dioxane, tetrahydrofuran, diethyl ether, toluene and benzene. More particularly preferred solvents are tetrahydrofuran and toluene. A suitable borane reducing agent is added to the reaction mixture and the reaction mixture is left at ambient temperature for 2 to 24 hours. The borane reducing agent may be selected from borane methylsulfide complex and borane tetrahydrofuran complex, but most preferred is borane methylsulfide complex. Generally the chiral oxazaborolidine catalyst will have formed within 10-16 hours.
After the chiral oxazaborolidine catalyst has formed, the prochiral ketone of formula (III) is added to the reaction mixture at ambient temperature. The reaction reducing the ketone to the alcohol is generally complete within 10-15 minutes after addition is complete. However, occasionally a longer amount of time may be required to ensure complete reaction depending upon a variety of factors including the particular solvents chosen or amounts of materials used and so on. The reaction mixture is then cooled, generally to about 0°C, and quenched by the careful addition of a proton source, generally methanol. The compound of formula (I) is isolated according to the standard methods of organic chemistry.
Alternatively, the reduction process of this invention can be carried out by reacting a prochiral ketone of the formula R4R5CO, wherein R4 and R5 are defined hereinbelow with a borane reducing agent in the presence of a chiral oxazaborolidine catalyst according to formula (V) or formula (VI). Said process results in the enantioselective reduction of said prochiral ketone, such that only one of two possible alcohol enantiomers is formed in preference to the corresponding enantiomer. The degree of enantio-selectivity which is obtained will vary depending upon the size of the R4 and R5 groups attached to the carbonyl group forming the prochiral ketone. When the R4 and Rs groups are similar in size, the degree of enantioselection will be lower. As the R4 and Rs groups become increasingly disparate in size, the degree of enantio¬ selection will be greater. However, it should be understood that the size of the R4 and R5 groups is not the sole determining factor affecting the degree of enantioselectivity achieved. Ordinarily, with prochiral ketones wherein R4 and R5 are at least moderately different in size, at least 90% of the desired enantiomer will be obtained. However, typically greater than 90% of the desired enantiomer is obtained
The prochiral ketone is dissolved in a suitable reaction inert solvent such as toluene, diethyl ether, dioxane, tetrahydrofuran or the like. Preferred is tetrahydrofuran. A catalytically effective amount of a chiral oxazaborolidine compound of formula (V) or formula (VI) is added to the reaction mixture at from about -78°C to about room temperature, preferably at room temperature; however, the preferred temperature will vary depending upon the particular borane reducing agent being used. The preferred amount of said catalyst is about 5-10 mole % with, respect to said ketone. The reaction mixture is then treated slowly with about 4.2 hydride equivalents of a borane reducing agent such as borane dimethylsulfide complex, borane tetrahydrofuran complex, catecholborane or the like. When the prochiral ketone contains an R4 or R5 group which bears a borane-coordinating functionality, additional hydride equivalents of reducing agent are necessary. Generally preferred for its ease of use is borane dimethylsulfide complex. Generally the reducing agent is added at a rate which modulates the rate of the catalytic reduction. The reaction is sometimes complete as soon as all of the reducing agent has been added, as can be determined by monitoring the course of the reaction via thin layer chromatography according to the standard practice of organic chemistry. However, occasionally it will be desirable to allow the reaction mixture to stir for longer periods of time such as overnight, or to heat the reaction mixture to temperatures of up to 40°C to 65°C in order to ensure completion of the reaction. Additionally, with some substrates and reducing agents, it may be necessary to stir the reaction mixture at -78°C for a lengthy period of time such as 16 hours. Ordinarily the reaction mixture is stirred at about room temperature for about fifteen minutes. The temperature of reaction mixture is then adjusted to 0°C and quenched with a proton source. Said proton source, usually a lower alkanol such as methanol, is added slowly to control the exothermic reaction. The product is isolated by removing the solvent in vacuo followed by partitioning between an organic solvent and an aqueous acid followed by separation of layers and purification according to the standard techniques of organic chemistry.
The compound of formula (II) of this process is also readily prepared. The compound of formula (I) is dissolved in aqueous base and vigorously stirred. The preferred base is sodium hydroxide, however other bases such as potassium hydroxide and potassium t-butoxide may also be utilized. The debromination and cyclization of the compound of formula (I) to the epoxide of formula (II) is effected rapidly and without racemization of the chiral center. Generally the reaction is complete within 5 to 10 minutes, however the reaction may require longer periods depending upon a variety of factors including strength of base, nature of base, amount of materials used and so on. After the epoxide is formed, the epoxide is isolated from the reaction mixture utilizing well-known methods of organic chemistry.
The prochiral ketone starting material for the process of this reaction is prepared by the method disclosed in U.S. Patent 4,886,814. The utility of these compounds as intermediates in the process for the preparation of the antidiabetic compound of formula (IV) is also described therein.
The chiral 1 ,2-disubstituted aminoethanol derivatives are generally readily available from commercial sources such as Aldrich or Sigma. Where the chiral 1 ,2- disubstituted aminoethanol derivative is not readily available, said erythro aminoethanol derivatives are prepared by methods well known to those of ordinary skill in the art, such as provided by Reetz et al., Angew. Chemie Int. Ed. Eng., 26, 1987, 1141-43 and Matsunaga et al., Tetrahedron Letters, 32, 1991. 7715-18.
The following terms and phrases, when used herein and in the appendant claims, are defined as follows:
1. "Alkyl" means a branched or unbranched saturated hydrocarbon group containing the specified number of carbon atoms, e.g., C-,-C8. Examples include, but are not limited to methyl, ethyl, isopropyl, n-butyl, t-butyl and the like.
2. "Alkoxy" means a branched or unbranched saturated hydrocarbon containing the specified number of carbon atoms and a single oxygen atom by which said hydrocarbon is attached to a central backbone. Examples include, but are not limited to methoxy, ethoxy and the like.
3. "Heterocyclyl" means a 5- or 6-membered aromatic group containing up to three heteroatoms, each of said heteroatoms selected from N, O and S and which may be optionally benzo-fused, said heterocyclyl group being optionally substituted independently with up to three (C-,-C8)alkyl, (C-,-C8)alkoxy or halo groups.
4. A "prochiral ketone", denoted by R4R CO, is a ketone in which R4 and R5 are non-identical, so that the secondary alcohol reduction product R4RsCHOH has a chiral center at the alcohol carbon. For cyclic prochiral ketones, it is understood that R4 and R5 are taken together, forming a ring including the ketone, and that the ring so formed has no plane of symmetry across a plane drawn perpendicular to the plane containing the carbonyl group and the two carbon atoms attached directly thereto, said plane containing both the carbon and oxygen atoms of the carbonyl group as points therein.
7. Reaction inert solvent means a solvent which does not interact with the reactants, intermediates or products in such a way that adversely affects the yield of the desired products. 8. "Syn" means that the substituents substituted on adjacent ring carbon atoms are located on the same side of a plane which encompasses the bond between said carbon atoms and the bonds by which each of said carbon atoms are attached to the ring.
9. "Enantiomeric excess", or e.e., is the excess of one of two enantiomers over the other, usually expressed as a percentage, i.e., a 90% e.e. reflects the presence of 95% of one enantiomer and 5% of the other in the material in question.
10. "Ambient temperature" means the temperature of the immediate external environment surrounding the reaction flask. This temperature is usually room temperature (20°-25°C).
11. In situ is the reaction condition wherein the chiral oxazaborolidines of formula (V) or formula (VI) of the invention are formed from the precursor aminoalcohol and borane. The prochiral ketone is added after the oxazaborolidine is generated. The chiral oxazaborolidines of the invention are not isolated under these conditions.
12. "Reaction inert atmosphere" means a gas which does not interact with the reactants, intermediates or products in such a way that adversely affects the yield of the desired products.
The present invention is illustrated by the following examples. However, it should be understood that the invention is not limited to the specific details of these examples. All reactions are conducted under an inert atmosphere, such as nitrogen or argon, unless otherwise specified. All solvents are anhydrous, i.e., contain such a small amount of water that said water does not interact with the reagents, intermediates or products in such a way that adversely affects the yield of the desired products. Where used herein, HF" means tetrahydrofuran. Example One (S)-Oxiranyl-2-trifluoromethylthiazole.
A. (S)-4-(2-Bromo-1 -hydroxyethyl)-2-trifluoromethylthiazole. To atetrahydrofuran
(55mL) solution of (1 S, 2R)-(+)-2-amino-1 ,2-diphenylethanol (586mg, 2.75mmol, 0.05 5 equivalents based on bromoketone) under a nitrogen atmosphere was added neat borane methylsulfide complex (Aldrich, ~10M, 7.70ml_, 77mmol, 1.4 equivalents based on bromoketone) all at once and allowed to stand 16hrs. (EIMS) M+ 223.1159 (Calcd
223.1168). Bromoketone III, (15.0g, 54.7mmol, 1.0 equivalent) in tetrahydrofuran
(28mL) was added dropwise over 1 hr at 25°C. Fifteen minutes after the addition was complete the starting ketone was consumed, the reaction was cooled to 0°C, quenched with methanol (55ml_), and stirred overnight. The solvents were removed under vacuum, toluene (140mL) was added to the residue, and the organic phase was washed successively with pH4 phosphate buffer (140ml_), water (140mL) and treated 5 with magnesium sulfate. Filtration and removal of the solvent under vacuum afforded the chiral alcohol as a pale yellow oil (13.58g, 90% mass balance, 94%ee).
B. (S)-Oxiranyl-2-trifluoromethylthiazole. Aqueous sodium hydroxide (4N, 12.52ml_) was added to the neat oil (13.42g) obtained in A. above with vigorous stirring. After 9 min. methylene chloride (100ml_) and water (100ml_) were added, the phases Q were separated, and the aqueous phase washed with water (3 x 100m L) and dried with magnesium sulfate. Filtration and removal of the solvent under vacuum afforded the crude chiral epoxide as an off white liquid, 9.35g. Distillation of 8.83g of the crude product at 4mmHg/boiling point 42-44°C yielded 6.99g (70% overall from the bromoketone) of the chiral epoxide as a colorless oil. 5 Example Two
(S)-4-(2-Bromo-1-hydroxyethyl)-2-trifluoromethylthiazole.
To a tetrahydrofuran (10ml_) solution of (1S, 2R)-(+)-norephedrine (76mg, O.δmmol) under a nitrogen atmosphere was added neat borane methylsulfide complex (10M , 1.4mL, 14mmole) at ambient temperature (20-25°C) and the reaction was allowed 0 to stand for 16 hrs. Bromoketone III, (2.74g, 10mmol) in tetrahydrofuran (5ml_) was added dropwise over 1 hr, the reaction stirred for 15 min after the addition was complete, then cooled to 0°C and quenched with methanol (10ml_). The quenched reaction was stirred for 18hr, the solvents were removed under vacuum and methylene chloride (25ml_) was added. The organic phase was washed successively with pH4 phosphate buffer (25ml_), water (25mL), and dried with magnesium sulfate. After filtering, the solvent was removed under vacuum to afford the (S) alcohol 2.24g as a yellow oil (83%, 84%ee).
Example Three
(S)-Oxiranyl-2-trifluoromethylthiazole
5
A. (S)-4-(2-Bromo-1 -hydroxyethyl)-2-trifluoromethylthiazole. Reduction intoluene and cyclization to the chiral epoxide. To a toluene (41 ml_) solution of (1 S, 2R)-2-amino 1 ,2-diphenylethanol (438mg, 2mmol, 0.05 equivalents based on bromoketone) under a nitrogen atmosphere was added neat borane methylsulfide complex (Aldrich, ~10M, 5.80ml_, 58mmol, 1.4 equivalents based on bromoketone) all at once and allowed to
10 stand 16 hrs. Bromoketone ((III), 11.31g, 41mmol, 1.0 equivalent) in toluene (21mL) was added dropwise over 1 hr at 25°C. Fifteen minutes after the addition was complete the starting ketone was consumed, the reaction was cooled to 0°C, quenched with methanol (41 mL), and stirred overnight. The solvents were removed under vacuum, toluene (100ml_) added to the residue, the organic phase washed successively with
15 aqueous sulfuric acid (1 M, 50m L), water (100mL), and treated with magnesium sulfate. Removal of the solvent under vacuum afforded the chiral alcohol as a pale yellow oil (10.84g, 95% mass balance, 90%ee).
B. (S)-Oxiranyl-2-trifluoromethyl thiazole. Aqueous sodium hydroxide (4N, _0 10.53ml_) was added to the neat oil (10.84g) with vigorous stirring. After 10 min., toluene (84m L) and water (84m L) were added, the phases separated, the aqueous phase washed with water (3 X 84mL) and dried with magnesium sulfate. Removal of the solvent under vacuum afforded the crude chiral epoxide as a off orange liquid, 6.50g. Distillation of 6.07g of the crude product at 4mmHg/boiling point 42-44°C 25 yielded 4.65g (61% overall from the bromoketone) of the chiral epoxide as a colorless oil.
30

Claims

Claims What is claimed is:
1. A process for enantioselectively preparing the compound of the formula
( I ) in substantially enantiomerically pure form, comprising: reacting the prochiral ketone of formula (III),
( I I I )
with a borane reducing agent in the presence of a chiral oxazaborolidine catalyst of the formula (V)
( V ) wherein R1 is hydrogen, (C,-C8)alkyl, benzyl, heterocyclyl or phenyl optionally substituted independently with up to three (C-,-C8)alkyl, (C.,-C8)alkoxy or halo groups; R2 and R3 are syn, are taken separately, and are each independently (C,-C8)alkyl, benzyl, heterocyclyl or phenyl optionally substituted with up to three (C-^C^alkyl, (C-,- C8)alkoxy or halo groups, provided that when R2 is CH3 and R3 is phenyl, R1 is H, or with a chiral oxazaborolidine catalyst of the formula (VI),
( V I )
wherein R1 is as defined above and D is a cis-fused 4-6 membered carbomonocyclic ring optionally substituted independently with up to three (C,-C8)alkyl, heterocyclyl or phenyl optionally substituted independently with up to three (C^C^alkyl, (C-,-C8)alkoxy or halo groups; a cis-fused 6-9 membered carbobicyclic system optionally substituted independently with up to three (O,-C8)alkyl, heterocyclyl or phenyl optionally substituted independently with up to three (C1-C8)alkyl, (C-,-C8)alkoxy or halo groups; or a cis-fused
system having the structure wherein R6 and R7 are each independently
H, (C-,-C8)alkyl, (C,-C8)alkoxy or halo, in a reaction inert solvent under a reaction inert atmosphere.
2. A process according to claim 1 wherein said oxazaborolidine catalyst is
( V I I ) ( V I I I )
3. A process according to claim 2 wherein said reaction inert solvent is tetrahydrofuran, dioxane, diethyl ether, toluene or benzene.
4. A process according to claim 3 wherein said reaction inert atmosphere is nitrogen, said borane reducing agent is borane methylsulfide complex and the temperature of the reaction mixture is maintained at ambient temperature.
5. A process according to claim 4 wherein said reaction inert solvent is tetrahydrofuran.
6. A process according to claim 5 wherein said chiral oxazaborolidine catalyst is prepared in situ by reacting said borane methylsulfide complex with (1 S, 2R)- 2-amino-1 ,2-amino-1 ,2-diphenylethanol prior to the addition of said prochiral ketone.
7. A process according to claim 5 wherein said chiral oxazaborolidine catalyst is prepared in situ by reacting said borane methylsulfide complex with (1 S, 2R)- (+)-norephedriηe prior to the addition of said prochiral ketone.
8. A process according to claim 4 wherein said reaction inert solvent is toluene.
9. A process according to claim 8 wherein said chiral oxazaborolidine catalyst is prepared in situ by reacting said borane methylsulfide complex with (1 S, 2R)- 2-amino-1 ,2-diphenylethanol prior to the addition of said prochiral ketone.
10. A process according to claim 8 wherein said chiral oxazaborolidine catalyst is prepared in situ by reacting said borane methylsulfide complex with (1 S, 2R)- (+)-norephedrine prior to the addition of said prochiral ketone.
11. A process for preparing the compound of formula (II),
( I I )
comprising enantioselectively preparing the compound of formula (I) according to the process of claim 1 and reacting said compound of formula (I) with a base to form said compound of formula (II).
12. A process according to claim 11 wherein said base is sodium hydroxide.
13. A process according to claim 12 wherein said borane reducing agent is borane methylsulfide complex, said reaction inert solvent is toluene, said reaction inert atmosphere is nitrogen, the temperature of the reaction mixture is ambient temperature and the chiral oxazaborolidine catalyst is prepared in situ by reacting said borane methylsulfide complex with (1 S, 2R)-(+)-norephedrine.
14. A process according to claim 12 wherein said borane reducing agent is borane methylsulfide complex, said reaction inert solvent is tetrahydrofuran, said reaction inert atmosphere is nitrogen, the temperature of the reaction mixture is ambient temperature and the chiral oxazaborolidine catalyst is prepared in situ by reacting said borane methylsulfide complex with (1 S, 2R)-(+)-norephedrine.
15. A process according to claim 12 wherein said borane reducing agent is borane methylsulfide complex, said reaction inert solvent is toluene, said reaction inert atmosphere is nitrogen, the temperature of the reaction mixture is ambient temperature and the chiral oxazaborolidine catalyst is prepared in situ by reacting said borane methylsulfide complex with (1 S, 2R)-(+)-2-amino-1 ,2-diphenyl ethanol.
16. A process according to claim 12 wherein said borane reducing agent is borane methylsulfide complex, said reaction inert solvent is tetrahydrofuran, said reaction inert atmosphere is nitrogen, the temperature of the reaction mixture is ambient temperature and the chiral oxazaborolidine catalyst is prepared in situ by reacting said borane methylsulfide complex with (1S, 2R)-(+)-2-amino-1 ,2-diphenyl ethanol.
EP94910017A 1993-07-16 1994-04-06 Enanthioselective preparation of thiazole derivatives Withdrawn EP0708764A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9283293A 1993-07-16 1993-07-16
PCT/IB1994/000062 WO1995002585A1 (en) 1993-07-16 1994-04-06 Enanthioselective preparation of thiazole derivatives
US92832 1998-06-05

Publications (1)

Publication Number Publication Date
EP0708764A1 true EP0708764A1 (en) 1996-05-01

Family

ID=22235378

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94910017A Withdrawn EP0708764A1 (en) 1993-07-16 1994-04-06 Enanthioselective preparation of thiazole derivatives

Country Status (5)

Country Link
EP (1) EP0708764A1 (en)
JP (1) JPH08507310A (en)
CA (1) CA2167287A1 (en)
FI (1) FI960180A (en)
WO (1) WO1995002585A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943635A (en) * 1987-08-27 1990-07-24 President & Fellows Of Harvard College Enantioselective reduction of ketones
HUT70422A (en) * 1991-07-22 1995-10-30 Pfizer Chiral thiazole derivatives and process for preparing them
CA2134096C (en) * 1992-05-14 1997-11-25 George J. Quallich Enantioselective oxazaborolidine catalysts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9502585A1 *

Also Published As

Publication number Publication date
FI960180A0 (en) 1996-01-15
FI960180A (en) 1996-01-15
JPH08507310A (en) 1996-08-06
CA2167287A1 (en) 1995-01-26
WO1995002585A1 (en) 1995-01-26

Similar Documents

Publication Publication Date Title
EP0698028B1 (en) Enantioselective oxazaborolidine catalysts
KR0149208B1 (en) Enantioselective oxazaborolidine catalysts
EP0763005B1 (en) TETRAHYDROINDENO[1,2-d][1,3,2]OXAZABOROLES AND THEIR USE AS ENANTIOSELECTIVE CATALYSTS
RU2150472C1 (en) Method of synthesis of diisopinocampheylchloroborane in reaction mixture, method of reduction of prochiral ketone
WO1995002585A1 (en) Enanthioselective preparation of thiazole derivatives
US6509472B2 (en) 4-Cyclohexyl-1,3,2-oxazaborolidine chiral accessories
CN117777057A (en) Synthesis method of chiral gamma-amino alcohol
CN115477667A (en) Preparation method of chiral silicon-containing stereocenter tetra-substituted silane compound

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951227

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19960430

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980310